ChronoScale Holdings extended the Maturity of its $2.0 million outstanding term Loan to November 12, 2026. The amendment also permits the sale of Ekso Bionics, Inc. without treating it as a change of control, while requiring related liens on sold Collateral to be released automatically without payment to the lender.
Key Highlights
- The amended agreement retains a maturity trigger tied to receipt of $2.4 million in net equity-sale proceeds.
- A sale of Ekso Bionics, Inc. is defined as a Permitted Disposition and does not constitute a Change of Control.
- Liens on Assets or Capital Stock sold in a Permitted Disposition are released automatically without payment to B. Riley Commercial Capital.
ChronoScale Holdings Corp (NASDAQ: CHRN) has extended the maturity of its $2.0 million outstanding term loan to November 12, 2026. The amendment also allows a sale of Ekso Bionics, Inc. to qualify as a Permitted Disposition, with related collateral releases built into the agreement.
Term Loan Amendment Extends Repayment Date
ChronoScale Intermediate, LLC, formerly Ekso Bionics Holdings, Inc. is the borrower, while Ekso Bionics, Inc. serves as guarantor. The amendment was entered into on September 12, 2026. Other material provisions remain unchanged, and the loan parties confirmed an outstanding principal balance of $2,000,000.
Sale Provisions Define Collateral Release
The amended agreement defines a Permitted Disposition as the sale of the guarantor through an asset sale, capital-stock sale, Merger or another structure. Such a transaction is excluded from the agreement’s definition of Change of Control. The borrower may submit UCC-3 termination statements on the lender’s behalf where permitted, while liens on other collateral continue securing the loan obligations.
FAQs
Q: What is ChronoScale Holdings’ new term loan maturity date?
A: ChronoScale Holdings’ amended term loan maturity date is November 12, 2026. The agreement still includes a separate maturity trigger tied to $2.4 million in net equity-sale proceeds.
Q: How does the amendment affect a sale of Ekso Bionics?
A: The sale of Ekso Bionics, Inc. is classified as a Permitted Disposition. It does not constitute a Change of Control under the amended loan agreement.
Q: What happens to liens when a permitted sale closes?
A: Liens and security interests on the sold collateral are automatically released when the transaction closes. No payment to B. Riley Commercial Capital is required as a condition of that release.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.